F2G Biotech GmbH

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia

Interventions: Drug: F901318 with posaconazole
Drug: F901318 with fluconazole high dose
Drug: F901318 with fluconazole low dose

First Posted Date: 2017-01-30

Last Posted Date: 2018-02-15

Lead Sponsor: F2G Biotech GmbH

Registration Number: NCT03036046

Radiolabelled IV and Oral Metabolism Study of F901318

Phase 1

Withdrawn

Conditions: Invasive Aspergillosis

Interventions: Drug: IV F901318
Drug: Oral F901318

First Posted Date: 2016-09-23

Last Posted Date: 2019-07-26

Lead Sponsor: F2G Biotech GmbH

Registration Number: NCT02912026

Locations: 🇬🇧
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

Phase 1

Withdrawn

Conditions: Pulmonary Aspergillosis - Invasive
Acute Myeloid Leukemia

Interventions: Drug: F901318
Drug: Caspofungin

First Posted Date: 2016-08-04

Last Posted Date: 2018-02-15

Lead Sponsor: F2G Biotech GmbH

Registration Number: NCT02856178

Evaluation of Immediate Release Tablet

Phase 1

Completed

Conditions: Invasive Aspergillosis

Interventions: Drug: F901318 IR Fed
Drug: F901318 SDD
Drug: F901318 IR
Drug: F901318 IR Fasting

First Posted Date: 2016-06-22

Last Posted Date: 2016-11-28

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 20

Registration Number: NCT02808741

Locations: 🇬🇧
Quotient Clinical, Nottingham, United Kingdom

Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects

Phase 1

Completed

Conditions: Invasive Aspergillosis

Interventions: Drug: Placebo Dose level C oral
Drug: F901318 Dose level C oral
Drug: F901318 Dose level A oral
Drug: Placebo dose level A oral
Drug: F901318 Dose level B oral
Drug: Placebo dose level B oral

First Posted Date: 2016-04-13

Last Posted Date: 2017-05-23

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 40

Registration Number: NCT02737371

Locations: 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, Glamorgan, United Kingdom

Study of Potential for Interaction of Fluconazole With F901318

Phase 1

Completed

Conditions: Invasive Aspergillosis

Interventions: Drug: F901318
Drug: Fluconazole

First Posted Date: 2016-04-06

Last Posted Date: 2017-02-02

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 20

Registration Number: NCT02730442

Locations: 🇬🇧
CELERION, Belfast, Northern Ireland, United Kingdom

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Phase 1

Completed

Conditions: Invasive Aspergillosis

Interventions: Drug: Midazolam with F901318

First Posted Date: 2016-02-12

Last Posted Date: 2016-06-09

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 20

Registration Number: NCT02680808

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Single Ascending Oral Dose Study of F901318

Phase 1

Completed

Conditions: Invasive Aspergillosis

Interventions: Other: Placebo safety
Drug: F901318 safety
Other: Placebo tolerability
Drug: F901318 tolerability
Other: Placebo pharmacokinetics
Drug: F901318 pharmacokinetics

First Posted Date: 2015-03-20

Last Posted Date: 2016-09-19

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 46

Registration Number: NCT02394483

Locations: 🇬🇧
Simbec Orion, Merthyr Tydfil, Wales, United Kingdom

F901318 Multiple Ascending Dose Study

Phase 1

Completed

Conditions: Invasive Aspergillosis

Interventions: Drug: Placebo
Drug: F901318

First Posted Date: 2015-01-21

Last Posted Date: 2016-09-19

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 72

Registration Number: NCT02342574

Locations: 🇬🇧
Hammersmith Medicines Research, London, UK, United Kingdom

F901318 Single Ascending Dose Study in Healthy Male Volunteers

Phase 1

Completed

Conditions: Invasive Aspergillosis

Interventions: Drug: F901318
Drug: Placebo

First Posted Date: 2014-05-20

Last Posted Date: 2015-09-07

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 40

Registration Number: NCT02142153

Locations: 🇬🇧
Simbec Research, Merthyr Tydfil, Mid Glamorgan, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy